Live attenuated virus vaccines for La Crosse virus and other bunyaviridae

US10561724B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Stephen S. Whitehead · Montgomery Village, US
• Richard S. Bennett · North Potomac, US
• Brian R. Murphy · Bethesda, US

Key dates

• Filing date: Jan 4, 2019
• Grant date: Feb 18, 2020
• Expiry date: Jan 4, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2760/12034
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to vaccine compositions including CEV serogroup immunogens, attenuated and inactivated viruses of the CEV serogroup and chimeric Bunyaviridae. Also disclosed are methods of treating or preventing CEV serogroup infection in a mammalian host, methods of producing a subunit vaccine composition or an immunogenic composition, isolated polynucleotides comprising a nucleotide sequence encoding a CEV serogroup immunogen, methods for detecting La Crosse virus (LACV) infection in a biological sample and infectious chimeric Bunyaviridae.